Rhumbline Advisers raised its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 5.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 181,230 shares of the company's stock after purchasing an additional 9,416 shares during the quarter. Rhumbline Advisers owned 0.14% of Vaxcyte worth $6,843,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also bought and sold shares of the stock. Whipplewood Advisors LLC purchased a new position in Vaxcyte in the 4th quarter worth about $28,000. Smartleaf Asset Management LLC lifted its position in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares during the last quarter. National Bank of Canada FI purchased a new stake in Vaxcyte in the fourth quarter worth $41,000. Blue Trust Inc. increased its stake in Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after purchasing an additional 371 shares during the period. Finally, Parallel Advisors LLC increased its stake in shares of Vaxcyte by 203.6% during the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after buying an additional 1,071 shares during the period. 96.78% of the stock is currently owned by institutional investors.
Vaxcyte Stock Performance
Shares of PCVX traded up $0.10 during trading hours on Friday, hitting $34.56. 1,186,805 shares of the stock were exchanged, compared to its average volume of 1,449,107. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06. The company has a market cap of $4.46 billion, a price-to-earnings ratio of -7.51 and a beta of 1.20. The stock's 50-day moving average price is $32.67 and its two-hundred day moving average price is $63.03.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter last year, the business earned ($0.85) earnings per share. On average, research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.
Analysts Set New Price Targets
Several equities research analysts have weighed in on PCVX shares. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Guggenheim reaffirmed a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. Cantor Fitzgerald began coverage on Vaxcyte in a report on Tuesday, April 22nd. They set an "overweight" rating for the company. Finally, The Goldman Sachs Group decreased their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $136.50.
Read Our Latest Analysis on PCVX
Vaxcyte Company Profile
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Featured Stories

Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.